BioCryst

H.C. Wainwright Reiterates Bullish View On BioCryst Pharmaceuticals Following 4Q:14 Update

In a research report published Thursday, H.C.

Ben Mahaney, Editor — February 19, 2015, 5:05 PM EDT

Roth Capital Reiterates Bullish Stance On BioCryst Pharmaceuticals Following FDA Fast-Track Status

Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, following the news that the FDA …

Jason Cohen Jason Cohen — January 27, 2015, 3:22 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts